Physician profile
Jayson D Edwards
NPI 1568697464
$1,044.84
in general payments reported to CMS, 2019-2025
15 companies · $94.01 in 2025
The $94.01 reported for 2025 was less than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $87.58 · 2021: $72.17 · 2022: $90.26 · 2023: $104 · 2024: $232 · 2025: $94.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $410.90 | 2019-2024 | |
| Alcon Vision LLC | $187.22 | 2021-2025 | Clareon Panoptix Pro, Clareon |
| New World Medical,INC. | $85.87 | 2023 | |
| Sight Sciences, INC. | $69.63 | 2019 | |
| Glaukos Corporation | $45.53 | 2020-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Abbott Laboratories | $42.99 | 2019-2020 | |
| Allergan, INC. | $39.42 | 2021 | |
| Sun Pharmaceutical Industries INC. | $27.34 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $26.03 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $24.91 | 2020 | |
| Oyster Point Pharma, INC. | $21.46 | 2024 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $18.09 | 2022 | |
| Tearlab Corp | $15.42 | 2024 | Scoutpro Osmolarity System |
| Abbvie INC. | $15.27 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayson Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.